Skip to main content
Premium Trial:

Request an Annual Quote

BioMark Dx, TMIC Partner on Cancer Metabolomics Research

NEW YORK (GenomeWeb) – BioMark Diagnostics today announced it is partnering with The Metabolomics Innovation Centre on cancer research. 

The deal augments BioMark's efforts to discover, validate, and translate metabolomics-based diagnostic tests for early cancer detection, the Vancouver, British Columbia-based firm said, adding it "complements" its planned research into lung, prostate, breast, and colon cancer.  

In collaboration with TMIC, BioMark plans to develop novel point-of-care diagnostic tests. 

BioMark develops non-invasive technologies to detect cancers, monitor patients, and assess disease treatments. TMIC is a Genome Canada-funded Science & Technology Innovation Centre for metabolomics research, technology development, and services. Its technologies are based on mass spectrometry, NMR, gas chromatography, and novel bioinformatics tools. 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.